Home
Storia in 1 fonti
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
Raccontata da
biopharmadive.com
- ·
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million…
- ·
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue…